Cardio-oncology: what you need to know now for clinical practice and echocardiography

Echo Research and Practice - 2017
Charlotte M Larsen1, Sharon L. Mulvagh1
1Department of Cardiovascular Medicine, Mayo Clinic, Rochester, Minnesota, USA.

Tóm tắt

Cardio-oncology is a rapidly growing field aimed at minimizing the effects of cardiovascular morbidity and mortality in cancer survivors. To meet this aim, patients are assessed at baseline to define their risk of cardiotoxicity and then followed closely during and after chemotherapy to assess for early signs or symptoms of cardiovascular disease. Cardiac imaging, and in particular, transthoracic echocardiography, plays an essential role in the baseline assessment and serial follow-up of cardio-oncology patients. The objectives of this paper are to review the mechanisms of cardiotoxicity of several common chemotherapeutic agents associated with an increased risk for left ventricular systolic dysfunction and to outline recommendations regarding the baseline assessment and serial follow-up of cardio-oncology patients with a focus on the role of echocardiography.

Từ khóa


Tài liệu tham khảo

1991, Exercise echocardiography in the detection of anthracycline cardiotoxicity, Cancer, 68, 435, 10.1002/1097-0142(19910715)68:2<435::AID-CNCR2820680237>3.0.CO;2-#

2015, Chronic statin administration may attenuate early anthracycline-associated declines in left ventricular ejection function, Canadian Journal of Cardiology, 31, 302, 10.1016/j.cjca.2014.11.020

2004, Prognostic value of troponin I in cardiac risk stratification of cancer patients undergoing high-dose chemotherapy, Circulation, 109, 2749, 10.1161/01.CIR.0000130926.51766.CC

2016, Cancer treatment and survivorship statistics, CA: A Cancer Journal for Clinicians, 66, 271

2013, Role of cardioprotective therapy for prevention of cardiotoxicity with chemotherapy: a systematic review and meta-analysis, European Journal of Cancer, 49, 2900, 10.1016/j.ejca.2013.04.030

2015, Chronic statin administration may attenuate early anthracycline-associated declines in left ventricular ejection function, Canadian Journal of Cardiology, 31, 302, 10.1016/j.cjca.2014.11.020

2010, Cardiotoxicity of anticancer drugs: the need for cardio-oncology and cardio-oncological prevention, Journal of the National Cancer Institute, 102, 14, 10.1093/jnci/djp440

JesusJMHouston, EckelRHJakicicJMArdJDde AHA ACC guideline on lifestyle management to reduce cardiovascular risk : a report of the American College of Cardiology Heart Association Task Force on Practice Guidelines, American Circulation, 2014, 10.1161/01.cir.0000437740.48606.dl

2010, Cardiotoxicity of anticancer treatments: what the cardiologist needs to know, Nature Reviews Cardiology, 7, 564, 10.1038/nrcardio.2010.121

2014, An update on cardio-oncology, Trends in Cardiovascular Medicine, 24, 285, 10.1016/j.tcm.2014.07.003

2014, Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging, European Heart Journal: Cardiovascular Imaging, 15, 1063

2016, Tyrosine kinase inhibitors and vascular toxicity: impetus for a classification system?, Current Oncology Reports, 18, 33, 10.1007/s11912-016-0514-0

2010, Cardiotoxicity of anthracycline agents for the treatment of cancer: systematic review and meta-analysis of randomised controlled trials, BMC Cancer, 10, 337, 10.1186/1471-2407-10-337

2012, Risk of heart failure in breast cancer patients after anthracycline and trastuzumab treatment: a retrospective cohort study, Journal of the National Cancer Institute, 104, 1293, 10.1093/jnci/djs317

2011, Anthracycline cardiotoxicity: prevalence, pathogenesis and treatment., Current Cardiology Reviews, 7, 214

2009, Cancer prevalence in the United Kingdom: estimates for 2008, British Journal of Cancer, 101, 541, 10.1038/sj.bjc.6605148

2013, Preventive effect of low-dose carvedilol combined with candesartan on the cardiotoxicity of anthracycline drugs in the adjuvant chemotherapy of breast cancer, Zhonghua Zhong Liu Za Zhi, 35, 936

2010, Anthracycline-induced cardiomyopathy: clinical relevance and response to pharmacologic therapy, Journal of the American College of Cardiology, 55, 213, 10.1016/j.jacc.2009.03.095

2004, Prognostic value of troponin I in cardiac risk stratification of cancer patients undergoing high-dose chemotherapy, Circulation, 109, 2749, 10.1161/01.CIR.0000130926.51766.CC

2015, Assessing anthracycline-treated childhood cancer survivors with advanced stress echocardiography, Pediatric Blood and Cancer, 62, 502, 10.1002/pbc.25328

2010, Left ventricular dysfunction in patients receiving cardiotoxic cancer therapies are clinicians responding optimally?, Journal of the American College of Cardiology, 56, 1644, 10.1016/j.jacc.2010.07.023

2013, Role of cardioprotective therapy for prevention of cardiotoxicity with chemotherapy: a systematic review and meta-analysis, European Journal of Cancer, 49, 2900, 10.1016/j.ejca.2013.04.030

2006, Early reduction in left ventricular contractile reserve detected by dobutamine stress echo predicts high-dose chemotherapy-induced cardiac toxicity, International Journal of Cardiology, 111, 120, 10.1016/j.ijcard.2005.07.029

2014, Prevention of anthracycline-induced cardiotoxicity: challenges and opportunities., Journal of the American College of Cardiology, 64, 938, 10.1016/j.jacc.2014.06.1167

JesusJMHouston, EckelRHJakicicJMArdJDde AHA ACC guideline on lifestyle management to reduce cardiovascular risk : a report of the American College of Cardiology Heart Association Task Force on Practice Guidelines, American Circulation, 2014, 10.1161/01.cir.0000437740.48606.dl

2014, Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging, European Heart Journal: Cardiovascular Imaging, 15, 1063

SCAI, 2016, expert consensus statement : evaluation management and special considerations of cardio - oncology patients in the cardiac catheterization laboratory ( endorsed by the cardiological society of india and sociedad Latino Americana de Cardiologia, Catheterization, 87, 10.1002/ccd.26379

2004, Essential roles of Her2/erbB2 in cardiac development and function, Recent Progress in Hormone Research, 59, 1, 10.1210/rp.59.1.1

2012, Risk of heart failure in breast cancer patients after anthracycline and trastuzumab treatment: a retrospective cohort study, Journal of the National Cancer Institute, 104, 1293, 10.1093/jnci/djs317

2006, Evaluation of cardiac reserved function by high-dose dobutamine-stress echocardiography in asymptomatic anthracycline-treated survivors of childhood cancer, Pediatrics International, 48, 313, 10.1111/j.1442-200X.2006.02210.x

2009, Cancer prevalence in the United Kingdom: estimates for 2008, British Journal of Cancer, 101, 541, 10.1038/sj.bjc.6605148

2006, Evaluation of cardiac reserved function by high-dose dobutamine-stress echocardiography in asymptomatic anthracycline-treated survivors of childhood cancer, Pediatrics International, 48, 313, 10.1111/j.1442-200X.2006.02210.x

ACCF, AHA guideline for the management of heart failure : a report of the American College of Cardiology Foundation Heart Association Task Force on Practice Guidelines of the of, American Journal American College Cardiology, 147

2010, Left ventricular dysfunction in patients receiving cardiotoxic cancer therapies are clinicians responding optimally?, Journal of the American College of Cardiology, 56, 1644, 10.1016/j.jacc.2010.07.023

2016, Prevention of cardiac dysfunction during adjuvant breast cancer therapy (PRADA): a 2 × 2 factorial, randomized, placebo-controlled, double-blind clinical trial of candesartan and metoprolol, European Heart Journal, 37, 1671, 10.1093/eurheartj/ehw022

2010, Cardiotoxicity of anthracycline agents for the treatment of cancer: systematic review and meta-analysis of randomised controlled trials, BMC Cancer, 10, 337, 10.1186/1471-2407-10-337

2014, Utility of 3-dimensional echocardiography, global longitudinal strain, and exercise stress echocardiography to detect cardiac dysfunction in breast cancer patients treated with doxorubicin-containing adjuvant therapy, Breast Cancer Research and Treatment, 143, 531, 10.1007/s10549-013-2818-1

2014, Use of myocardial strain imaging by echocardiography for the early detection of cardiotoxicity in patients during and after cancer chemotherapy: a systematic review, Journal of the American College of Cardiology, 63, 2751, 10.1016/j.jacc.2014.01.073

2015, Assessing anthracycline-treated childhood cancer survivors with advanced stress echocardiography, Pediatric Blood and Cancer, 62, 502, 10.1002/pbc.25328

2016, Cancer treatment and survivorship statistics, CA: A Cancer Journal for Clinicians, 66, 271

2014, Evaluation and management of patients with heart disease and cancer: cardio-oncology, Mayo Clinic Proceedings, 89, 1287, 10.1016/j.mayocp.2014.05.013

2010, Anthracycline-induced cardiomyopathy: clinical relevance and response to pharmacologic therapy, Journal of the American College of Cardiology, 55, 213, 10.1016/j.jacc.2009.03.095

2014, Evaluation and management of patients with heart disease and cancer: cardio-oncology, Mayo Clinic Proceedings, 89, 1287, 10.1016/j.mayocp.2014.05.013

2014, Routine echocardiography screening for asymptomatic left ventricular dysfunction in childhood cancer survivors: a model-based estimation of the clinical and economic effects, Annals of Internal Medicine, 160, 661, 10.7326/M13-2266

2006, Early reduction in left ventricular contractile reserve detected by dobutamine stress echo predicts high-dose chemotherapy-induced cardiac toxicity, International Journal of Cardiology, 111, 120, 10.1016/j.ijcard.2005.07.029

ACCF, AHA guideline for the management of heart failure : a report of the American College of Cardiology Foundation Heart Association Task Force on Practice Guidelines of the of, American Journal American College Cardiology, 147

2014, Utility of 3-dimensional echocardiography, global longitudinal strain, and exercise stress echocardiography to detect cardiac dysfunction in breast cancer patients treated with doxorubicin-containing adjuvant therapy, Breast Cancer Research and Treatment, 143, 531, 10.1007/s10549-013-2818-1

SCAI, 2016, expert consensus statement : evaluation management and special considerations of cardio - oncology patients in the cardiac catheterization laboratory ( endorsed by the cardiological society of india and sociedad Latino Americana de Cardiologia, Catheterization, 87, 10.1002/ccd.26379

2016, Prevention of cardiac dysfunction during adjuvant breast cancer therapy (PRADA): a 2 × 2 factorial, randomized, placebo-controlled, double-blind clinical trial of candesartan and metoprolol, European Heart Journal, 37, 1671, 10.1093/eurheartj/ehw022

2014, Routine echocardiography screening for asymptomatic left ventricular dysfunction in childhood cancer survivors: a model-based estimation of the clinical and economic effects, Annals of Internal Medicine, 160, 661, 10.7326/M13-2266

2004, Essential roles of Her2/erbB2 in cardiac development and function, Recent Progress in Hormone Research, 59, 1, 10.1210/rp.59.1.1

2005, Type II chemotherapy-related cardiac dysfunction: time to recognize a new entity, Journal of Clinical Oncology, 23, 2900, 10.1200/JCO.2005.05.827

2016, Noninvasive measures of ventricular-arterial coupling and circumferential strain predict cancer therapeutics-related cardiac dysfunction, JACC: Cardiovascular Imaging, 9, 1131

2010, Cardiotoxicity of anticancer treatments: what the cardiologist needs to know, Nature Reviews Cardiology, 7, 564, 10.1038/nrcardio.2010.121

2014, Use of myocardial strain imaging by echocardiography for the early detection of cardiotoxicity in patients during and after cancer chemotherapy: a systematic review, Journal of the American College of Cardiology, 63, 2751, 10.1016/j.jacc.2014.01.073

2005, Type II chemotherapy-related cardiac dysfunction: time to recognize a new entity, Journal of Clinical Oncology, 23, 2900, 10.1200/JCO.2005.05.827

2011, Anthracycline cardiotoxicity: prevalence, pathogenesis and treatment., Current Cardiology Reviews, 7, 214

2014, An update on cardio-oncology, Trends in Cardiovascular Medicine, 24, 285, 10.1016/j.tcm.2014.07.003

ESMO, 2012, Cardiovascular toxicity induced by chemotherapy targeted agents and radiotherapy Guidelines of Supplement, Clinical Practice Annals Oncology, 23, 155, 10.1093/annonc/mds293

ESMO, 2012, Cardiovascular toxicity induced by chemotherapy targeted agents and radiotherapy Guidelines of Supplement, Clinical Practice Annals Oncology, 23, 155, 10.1093/annonc/mds293

2014, Prevention of anthracycline-induced cardiotoxicity: challenges and opportunities., Journal of the American College of Cardiology, 64, 938, 10.1016/j.jacc.2014.06.1167

1991, Exercise echocardiography in the detection of anthracycline cardiotoxicity, Cancer, 68, 435, 10.1002/1097-0142(19910715)68:2<435::AID-CNCR2820680237>3.0.CO;2-#

2010, Cardiotoxicity of anticancer drugs: the need for cardio-oncology and cardio-oncological prevention, Journal of the National Cancer Institute, 102, 14, 10.1093/jnci/djp440

2016, Tyrosine kinase inhibitors and vascular toxicity: impetus for a classification system?, Current Oncology Reports, 18, 33, 10.1007/s11912-016-0514-0

2013, Preventive effect of low-dose carvedilol combined with candesartan on the cardiotoxicity of anthracycline drugs in the adjuvant chemotherapy of breast cancer, Zhonghua Zhong Liu Za Zhi, 35, 936

2016, Noninvasive measures of ventricular-arterial coupling and circumferential strain predict cancer therapeutics-related cardiac dysfunction, JACC: Cardiovascular Imaging, 9, 1131

Thông tin
Thông tin xuất bản

Echo Research and Practice

Thông tin tác giả